December 20, 2016
BMS gets exclusive rights to study PsiOxus’s cancer drug
Bristol-Myers Squibb and PsiOxus Therapeutics have entered into an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical…